Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab +/- Cemiplimab in Advanced Malignancies (mCRPC, NSCLC)
NCT03367819Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of isatuximab in metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jan 2018; status: terminated.
02
Drugs
isatuximab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03367819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367819.